Compare KELYA & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | ENTA |
|---|---|---|
| Founded | 1946 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.1M | 378.0M |
| IPO Year | 1994 | 2012 |
| Metric | KELYA | ENTA |
|---|---|---|
| Price | $16.09 | $12.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $15.00 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 350.9K | 148.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $5,355,600,000.00 | $102,814,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | $107.07 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $7.98 | $7.05 |
| 52 Week High | $17.75 | $17.15 |
| Indicator | KELYA | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 43.94 |
| Support Level | $8.48 | $12.05 |
| Resistance Level | $16.20 | $13.84 |
| Average True Range (ATR) | 0.71 | 0.56 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 43.17 | 33.63 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.